CervoMed Shares Climb on Promising Biomarker Data for Dementia Treatment

CervoMed shares are trading higher after the company presented data showing their drug, neflamapimod, significantly improves biomarkers related to neuroinflammation and neurodegeneration in Dementia with Lewy Bodies.